Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month High – Here’s What Happened

Bicara Therapeutics Inc. (NASDAQ:BCAX) reached a new 52-week high during trading on Wednesday . The stock traded as high as $28.08 and last traded at $26.11, with a volume of 2883 shares trading hands. The stock had previously closed at $25.19.

Analyst Ratings Changes

A number of research firms have commented on BCAX. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a report on Tuesday. They issued a “buy” rating and a $48.00 price objective for the company. TD Cowen assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating for the company. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday. Morgan Stanley assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 target price for the company. Finally, Stifel Nicolaus assumed coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $43.33.

Bicara Therapeutics Price Performance

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the business’s stock in a transaction on Monday, September 16th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $32,994,000.00. Following the acquisition, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. In other Bicara Therapeutics news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the acquisition, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder James E. Flynn bought 70,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the purchase, the insider now owns 897,587 shares in the company, valued at approximately $16,156,566. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.